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A B S T R A C T
This is a protocol for a Cochrane Review (Diagnostic test accuracy). The objectives are as follows:
To determine the diagnostic accuracy of the rapid diagnostic test (RDT) based on the antigen F1 (F1RDT) for detecting plague in persons
with suspected disease.
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B A C K G R O U N D
Target condition being diagnosed
Plague has caused major historic pandemics including the "Plague
of Justinian" in the 6th century, the "Black Death" in the 14th cen-
tury (which resulted in the death of one-third of the European pop-
ulation), and the "Third Pandemic" in the 19th century (Rasmussen
2015). This severe disease remains a current threat in many parts
of the world, and has increased over the last few decades. Between
1989 and 2003, 38,310 human cases of plague were reported from
25 countries, including 2845 deaths (WHO 2019a). Since 2000, over
95% of the burden associated with plague has been concentrated
in Africa, particularly the Democratic Republic of the Congo (DRC),
Madagascar, Uganda and the United Republic of Tanzania (WHO
2016; WHO 2019a). Peru and the USA also regularly report cases.
Finally, although Asia is the region with the biggest natural foci of
the disease, the reservoir consists of gerbils and marmots; there is
a limited at-risk population in contact with these animals, so out-
breaks are sporadic (WHO 2016). As of 2017, the DRC, Madagascar
and Peru are the countries with the highest incidence of the dis-
ease. However, countries that have never experienced plague, or
not experienced plague for a long while, can be affected as the lim-
its of the existing foci are not fixed and new foci can emerge. Human
plague outbreaks are continuously being reported, from Indonesia
in 2007 and the DRC and Tanzania in 2014, to the large outbreak of
pneumonic plague more recently reported in Madagascar in 2017
(WHO 2009; WHO 2016; WHO 2019a).
Plague is caused by the bacteria Yersinia pestis. It is primarily a vec-
tor-borne zoonotic disease, affecting rodents and other wild and
domestic animals. It is most commonly transmitted to humans by
rodent fleas, leading to bubonic plague. Less frequently, plague can
be transmitted through scratches or bites from infected animals, di-
rect handling of infected animals, and human-to-human transmis-
sion by inhalation of droplets (CDC 2019; Weniger 1984).
Plague can affect both adults and children, with no differences be-
tween genders or ethnicities. However, the disease presents more
frequently among persons involved in activities with an increased
exposure to the disease, such as hunters, veterinarians, etc. Pover-
ty is also associated with a greater risk of contracting plague due to
increased exposure to rodents.
Plague is always a medical emergency and presents in a variety of
forms, with three major clinical syndromes. The bubonic plague is
the most common form and is characterized by enlarged lymph
nodes with necrotic areas called buboes. Pneumonic plague is a
fulminant form which affects the lungs and presents with cough
and bloody sputum. The pneumonic form can be primary (as a re-
sult of inhalation of droplets from infected humans or animals), or
secondary (as a result of the haematogenous spread of any oth-
er form of plague) (CIDRAP 2013). The third major clinical form is
septicaemic plague which occurs when the infection spreads to
the circulatory system; it can be primary (without buboes or pul-
monary affectation), or secondary (as a result of spreading bubon-
ic or pneumonic plague). Less commonly, plague can present as
meningitis (Prentice 2007).
Although efficient antimicrobials are available, plague still has a
high mortality rate as most outbreaks take place in remote places
in resource-limited settings, where proper diagnosis and treatment
remains challenging (WHO 2009). While bubonic plague is associat-
ed with case fatality ratios (CFRs) of 10% to 20%, pneumonic plague
is highly fatal, with a CFR close to 100% if leK untreated and over
50% when adequately treated with antimicrobials (Prentice 2007).
In addition to the sporadic cases and outbreaks, because of the
characteristics of the disease resulting in high mortality, Y pestis has
been used as a biological weapon and is currently a bioterrorism
threat (CDC 2019).
Due to its historical pandemics and high fatality rate, plague con-
tinues to cause fear and panic, and is sometimes associated with
a disproportionate public health response, which has considerable
social and economic consequences (Mavalankar 1995; Mead 2018).
A diagnostic tool that is quick to use and highly accurate would
help ensure appropriate response, especially in the context of out-
breaks.
Index test(s)
Rapid diagnostic tests (RDTs) detect pathogen-specific antigens in
a small quantity of different body fluids through lateral flow im-
munochromatography. RDTs are widely used in other diseases,
such as malaria (WHO 2019b). They are usually easy to use and to
interpret. Indeed, they can be performed at the bedside of the pa-
tient without the requirement of special equipment or laboratory
facilities. They give a simple result within around 15 minutes — pos-
itive or negative, at thresholds set by the manufacturer — that can
easily be interpreted by health workers without advanced training.
RDTs are therefore useful diagnostic tools for use at the community
level and in low-resource settings.
In the case of plague, the RDT detects the F1 capsular antigen of Y
pestis (F1RDT), which is present in large amounts in buboes, blood,
and sputum from patients infected with plague. F1RDT is the only
RDT for plague that has been developed for clinical purposes that
we are aware of. The test gives a semi-quantitative result within
15 minutes according to the intensity of the line (from 1+ to 4+),
although it is most commonly used as a qualitative test (positive
or negative result) where positivity is interpreted from 1+ (as soon
as the line is visible). The threshold for positivity will depend on
the manufacturer, and is established by the lower concentration of
the F1 antigen that the test can detect. The F1RDT can be used in
bubo aspirate, urine and sputum; it is not usually used in blood as
the pink result line would be difficult to see. Currently, the F1RDT
that is mainly being used in the field is produced in Madagascar.
The updated version was developed in 2001 (Chanteau 2003). Oth-
er F1RDTs for plague are produced by New Horizons in the USA, al-
though it is not licensed for use in humans (New Horizons 2019),
and in Taiwan (Hsu 2018). Storage conditions are indicated by each
manufacturer and are usually easy to comply with.
Clinical pathway
People of any age affected by plague will present with non-specif-
ic symptoms such as fever, chills, headache, or nausea; these are
associated with lymph node swelling in case of bubonic plague,
and/or cough, haemoptysis and chest pain for pneumonic plague.
While a first diagnosis of plague is suspected based on clinical find-
ings, the definitive diagnosis requires laboratory testing. Bacterio-
logical identification of Y pestis through microscopy or culture (or
both) is the reference standard for a confirmed case of plague. Y
pestis grows easily in standard culture media, and while bacteri-
ological isolation is highly specific, it is also highly sensitive un-
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der ideal conditions. However, administration of antibiotics prior
to sample collection is likely to lead to a false negative result. De-
lay in transportation from the time of collection to the central lab-
oratory (which is not uncommon in low-resource settings), associ-
ated or not with poor storage conditions, can lead to decreased vi-
ability of the pathogen and overgrowth of contaminating bacteria,
with subsequent false negative results. Another confirmatory diag-
nosis of plague is obtained by serology with a four-fold difference in
F1 antibody titres between paired serum samples, from acute and
convalescent phases. While this test is highly specific and allows di-
agnosis of true cases of plague, a limitation in practice is the obten-
tion of the second serum sample during the convalescence phase,
as people might return to their home or work setting as soon as
they feel well enough. Another technique more recently used in the
diagnosis of plague is polymerase chain reaction, targeting several
genes including the pla gene, encoding plasminogen activator, and
the caf1 gene, encoding F1 capsule antigen.
These diagnostic tests (culture, paired serology, and polymerase
chain reaction) require technology and qualified staI, which are
rarely available in resource-limited areas. In addition, results from
culture and paired serology take several days. These tests do not
allow a fast confirmation of plague diagnosis, and physicians can-
not rely on them for the acute management of patients. Therefore,
in practice, as soon as a case of plague is clinically suspected in
an area where plague is endemic (or if the case visited an endem-
ic area), the patient is immediately given antibiotics following col-
lection of biological samples (blood, sputum and/or bubo aspirate)
whenever possible, and managed as a case of plague until microbi-
ological diagnosis is confirmed or excluded, usually based on cul-
ture results. It is common that patients finish the treatment course
or evolve to a fatal outcome before plague is microbiologically con-
firmed. In addition, public health measures are established, espe-
cially for cases of pneumonic plague, including tracing contacts
and distributing chemoprophylaxis.
The use of the F1RDT, performed for all suspected cases of plague
during the first contact of the patient with healthcare facilities,
would support the clinical suspicion of plague when positive, and
guide physicians to consider other diseases when negative, provid-
ing valuable guidance for both clinical and public health response.
Prior test
It is very unlikely that patients will have had another diagnostic
test for detecting plague prior to presentation to the health facility
where the F1RDT would be performed, as the F1RDT should be per-
formed at the first point of presentation with medical facilities.
Role of index test
The role of the F1RDT is to provide bedside rapid results in the iden-
tification of patients with plague, to allow prompt treatment and to
establish preventive measures in order to limit transmission of the
disease to others in case of a positive result for pneumonic plague.
A negative F1RDT finding would prompt clinicians to consider oth-
er diagnoses for correct management of the patient and to avoid
unnecessary preventive measures that would be essential in case
of plague. An easy-to-use and accurate F1RDT for plague would
therefore be of considerable help in daily clinical practice for the
management of patients with suspicion of plague in endemic areas
by providing a fast diagnosis, as microbiological confirmation of
plague takes several days. The F1RDT would be used in addition to
the reference standard and would not replace culture, which is fun-
damental for assessing circulating strains and antibiotic resistance
testing. According to the specificity of the test, the F1RDT could be
used as a triage tool, meaning that a negative result would definite-
ly exclude plague, and that other tests — such as culture — would
only be collected in cases with a positive result, and managed ac-
cordingly.
The F1RDT cannot be used as a screening tool for plague in asymp-
tomatic patients, for example asymptomatic persons that have
been in contact with people suffering from plague. Indeed, samples
to perform the test are mainly bubo aspirate (in case of suspicion
of bubonic plague) and sputum (in case of pneumonic plague) and
those samples would be non-existent in asymptomatic persons.
Alternative test(s)
Direct enzyme-linked immunosorbent assay (ELISA) for detection
of the F1 antigen is another test used for the diagnosis of plague. It
requires equipment as well as trained personnel to perform it, and
it is not easily available in low-resource settings.
Rationale
Plague is a serious illness with high mortality and rapid trans-
mission from fleas or in between humans if control measures are
not immediately implemented. Given the non-specific symptoms
of plague (mainly for the pneumonic and septicaemic forms of
plague) and the measures to be implemented in the event of a con-
firmed case (such as surveillance measures, identification of con-
tacts for prophylaxis, and safe burial to avoid spread of the disease),
it is crucial to make a formal diagnosis of plague as soon as possi-
ble to distinguish it from other infections with similar clinical pre-
sentation. The delay in a confirmed diagnosis may have two main
repercussions. The first is at the individual level, as confirmation
or exclusion of the diagnosis will help optimize the patient's man-
agement, including consideration of alternative diseases and treat-
ments. The second is at a public health level, as pneumonic plague
can be transmitted from human to human, leading to outbreaks,
which are often associated with fear, panic, and sometimes with ex-
cessive measures that can lead to social and economic disruption,
with considerable consequences.
A highly accurate and fast diagnostic test would undoubtedly be
helpful. High accuracy of the test is imperative; indeed, low sensi-
tivity (i.e. high numbers of false negatives) would lead to missed
cases of plague in the situation where the test is used as a screen-
ing tool (i.e. to exclude plague diagnosis when a negative result is
observed and pursue with microbiological analysis when a positive
result is observed), and to initial mismanagement of the case until it
is confirmed microbiologically. Low specificity would probably lead
to a bigger concern. A false positive case might trigger unnecessary
social alert, avoidable anxiety to the patients and their family, and
avoidable use of resources, particularly in fragile health systems in
countries where plague is endemic (Mavalankar 1995; Mead 2018).
A highly specific test with a very low false positivity rate would allow
the adequate management of all negative cases, considering them
true negative cases.
Another important consideration to take into account while evalu-
ating the F1RDT is the use and importance of specificity of the test
in diagnosing patients with suspicion of pneumonic plague in the
context of an outbreak. The pneumonic form of plague is a very se-
vere and fatal disease that can be transmitted from human to hu-
man. Contrary to the bubonic form, where the presence of buboes
Rapid diagnostic tests for plague (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
3
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
might facilitate the suspicion of plague, symptoms presented with
the pneumonic plague are less specific. In addition, the obtention
of a good sample to run the F1RDT might be more difficult in the
pneumonic plague, where it might be challenging to obtain good-
quality sputum from children and from severely ill patients with
decreased consciousness. Performing the test in saliva instead of
sputum will certainly lead to different accuracy findings, and this
should be taken into account.
The F1RDT is a simple diagnostic tool that can be performed at the
bedside of the patient, with a fast result that allows prompt diag-
nosis and early treatment, as well as timely implementation of con-
trol measures to limit the spread of the disease. The F1RDT there-
fore has the potential to be useful to health workers, and could
contribute to reducing the high mortality attributed to plague, as
well as inadequate public health responses to it. However, there
is no systematic review assessing the diagnostic test accuracy of
the F1RDT for plague against standard diagnostic tests. Currently,
a confirmed case of plague is made either by isolation of Y pestis
(culture) or by acute and convalescent serological antibody testing
(four-fold difference in F1 antibody titres), according to WHO de-
finitions (WHO 2019a). Positivity of either test provides a reliable
diagnosis of plague and can be used interchangeably to consider
a case of plague (although culture is preferred in order to identify
the strain and resistance pattern). It is therefore reasonable to as-
sess the accuracy of the F1RDT against both these tests. With the
increasing inclusion of molecular biology for the diagnosis of many
infectious diseases, we thought it was relevant to also assess accu-
racy of the F1RDT against polymerase chain reaction.
The findings of this review will help to develop evidence-based rec-
ommendations on the role of the F1RDT in the diagnosis of plague,
which could be included in clinical guidelines about the manage-
ment of plague.
O B J E C T I V E S
To determine the diagnostic accuracy of the rapid diagnostic test
(RDT) based on the antigen F1 (F1RDT) for detecting plague in per-
sons with suspected disease.
Secondary objectives
To assess the effect of forms of plague (bubonic, septicaemic, or
pneumonic), specimen tested (bubonic aspirate, urine, or sputum),
prior antibiotic treatment, location where the test is performed
(field or laboratory studies), and threshold for detecting the disease
(as set by the manufacturer) on the accuracy of the F1RDT for de-
tecting the disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include cross-sectional studies that assess the accuracy of
the F1RDT for diagnosing plague in the laboratory or in field condi-
tions, where patients were tested for plague with both the F1RDT
and at least one of the reference standards (culture, polymerase
chain reaction, or serology). We will exclude case-control (two-gate
cross-sectional) studies as we aim to determine accuracy of the RDT
from only one set of participants, all of them with suspected plague.
Participants
We will include patients (including children and pregnant women)
living in or visiting areas where plague is endemic, who presented
to any healthcare facility (primary, secondary or tertiary care) with
clinical suspicion of any form of plague. For studies where only a
subgroup of participants is eligible for inclusion in the review, we
will include the study provided that there are disaggregated data
that we can extract for that subgroup.
Index tests
The index test we will assess is the F1RDT to detect plague.
Target conditions
The target condition is any form of plague (bubonic, septicaemic or
pneumonic).
Reference standards
We will include studies that use one of the following reference stan-
dards to diagnose plague.
• Isolation of Y pestis by culture.
• Polymerase chain reaction.
• Serology showing a four-fold difference in F1 antibody titres be-
tween two paired samples.
Search methods for identification of studies
We will attempt to identify all relevant studies regardless of lan-
guage, publication status, or publication date.
Electronic searches
We will search the following databases using the search terms and
strategy described in Appendix 1: the Cochrane Central Register
of Controlled Trials (CENTRAL, published in the Cochrane Library),
MEDLINE (PubMed), Embase (accessed via Ovid), Science Citation
Index (Web of Science). We will also search the WHO International
Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov for
trials in progress.
Searching other resources
We will search the proceedings and abstracts of relevant confer-
ences from the past five years. We will handsearch the reference
lists of relevant papers and contact researchers working in the field.
We will also search for related articles to the included studies using
the PubMed "similar articles" function.
Data collection and analysis
Selection of studies
Two review authors will independently screen all the abstracts re-
trieved by the search strategy, using the predefined eligibility crite-
ria. We will exclude studies that are clearly irrelevant based on the
titles and abstracts. We will retrieve full-text copies of the remaining
studies and apply the predefined criteria for inclusion in the review.
We will resolve any disagreements in assessment through discus-
sion, or by referral to the third review author when required. We will
list all studies excluded after full-text assessment in a ‘Characteris-
tics of excluded studies’ table. We will illustrate the study selection
process in a PRISMA diagram.
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Data extraction and management
Two review authors will independently conduct data extraction
and management, using data extraction forms. We will compare
these data and resolve any disagreement through discussion. For
each included study, we will gather information into ‘Characteris-
tics of included studies’ tables, comprising data on the following
(Appendix 2).
• Setting, design and duration of the study.
• Baseline characteristics of the study population and the sample
size.
• Target condition: forms of plague assessed.
• Index test used: name, detection target, need for sample prepa-
ration, personnel who conducted the test, training provided
to personnel for conducting the test, location where test per-
formed.
• Reference standard: test performed, personnel who conducted
the test, training provided to personnel for conducting the test,
location where test performed, conditions of storage and trans-
port.
• Results for both index and reference standard tests: missing cas-
es, uninterpretable results, true and false positives, true and
false negatives, sensitivity and specificity of index tests.
• Other relevant details such as source of funding.
Assessment of methodological quality
Two review authors will independently assess the methodological
quality of each included study, using the Quality Assessment of Di-
agnostic Accuracy Studies (QUADAS-2) tool, which is based on four
domains: patient selection, index test, reference standard, and flow
and timing (Whiting 2011). We have tailored the tool to the context
of this review (Appendix 3). We will answer each of the signalling
questions as either ‘yes’, ‘no’, or ‘unclear’, and give the reason for
our judgement. We will resolve any disagreement through discus-
sion and through consultation with a third review author in case of
persisting disagreement.
Statistical analysis and data synthesis
We will stratify all analyses by the reference standard used. Within
each stratum, we will construct a two-by-two table (containing the
number of true positive, true negative, false positive, and false neg-
ative results) for each study. Where only sensitivity and specificity
estimates are reported, we will attempt to derive the two-by-two
table from the reported data. We will enter the two-by-two data in-
to Review Manager 5 (RevMan 2014). Estimates of sensitivity and
specificity from each individual study will be summarized on forest
plots and plotted using summary receiver operating characteristic
(SROC) plots.
We will also calculate positive and negative predictive value esti-
mates for various scenarios to help interpret the impact of F1RDT
findings.
If meta-analysis is appropriate given the number of studies and ex-
tent of clinical heterogeneity, we will pool results from the included
studies. If there is little variation in threshold between studies, we
will use the bivariate model to obtain pooled estimates of sensitiv-
ity and specificity at common thresholds. The bivariate model will
be fitted using the metandi and xtmelogit commands in Stata ver-
sion 14 (Stata 2015). We will plot the pooled estimates of sensitiv-
ity and specificity using SROC plots in Review Manager 5 (RevMan
2014). If thresholds vary considerably between the included stud-
ies, we will plot the sensitivity and specificity for each study in ROC
space and use the hierarchical summary receiver operating charac-
teristic (HSROC) model to estimate a SROC curve. The HSROC mod-
el will be fitted using PROC NLMIXED in the SAS software (SAS 2011).
We may estimate both summary sensitivity and specificity points,
and SROC curves, if both methods will produce clinically useful in-
formation.
Investigations of heterogeneity
If data are available, we will assess the impact of the following vari-
ables on accuracy of F1RDTs by performing subgroup analyses or
meta-regression (by inclusion as a covariate in the bivariate model
— using xtmelogit — or the HSROC model).
• Forms of plague (bubonic, septicaemic, and pneumonic).
• Specimen tested (bubonic aspirate, urine, and sputum).
• Prior antibiotic treatment.
• Location of performance of the F1RDT (field and laboratory).
• Threshold for detecting the disease (as set by the manufacturer).
We will stratify the findings by type of reference standard used: bac-
terial isolation by culture, polymerase chain reaction, and serolo-
gy showing a four-fold difference in F1 antibody titres between two
samples from acute and convalescent phases.
Sensitivity analyses
We may perform a sensitivity analysis in which we only include
studies that have a low risk of bias for the four domains (patient
selection, index test, reference standard, and flow and timing). We
may also conduct a sensitivity analysis restricted to those studies
at low risk of bias for patient selection only. We will compare these
results with those including all included studies, to investigate the
robustness of the diagnostic accuracy estimates.
Assessment of reporting bias
Little is known on how to assess and detect reporting bias for di-
agnostic test accuracy studies (Macaskill 2010). We may test for as-
sociation between the natural-logarithm of the diagnostic odds ra-
tio (lnDOR) and the "effective sample size", a simple function of
the number of diseased and non-diseased individuals (Deeks 2005).
However, this test has low power for detecting funnel plot asymme-
try when there is heterogeneity in the diagnostic odds ratio (DOR).
If funnel plot asymmetry is detected, we will explore potential rea-
sons for this association between study size and test accuracy, as
reporting bias may not necessarily be the cause.
Assessment of the certainty of the evidence
We will assess the certainty of the evidence using the GRADE princi-
ples and GRADEpro GDT software (GRADE Handbook 2013; GRADE-
pro GDT 2015). We will rate the certainty of the evidence as either
high, moderate, low or very low by assessing four domains (risk of
bias, indirectness, inconsistency and imprecision), as follows.
• Risk of bias: we will assess risk of bias by using the QUADAS-2
tool.
• Indirectness: we will use the QUADAS-2 tool to assess applica-
bility concerns and look for important differences between the
populations studied, the setting, and the review question.
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Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• Inconsistency: we will explore inconsistency by investigating po-
tential sources of heterogeneity, and we will downgrade the cer-
tainty of the evidence when we cannot explain inconsistency in
the accuracy estimates.
• Imprecision: we will consider the width of the confidence inter-
vals (CIs) and question whether the truth set at the lower or up-
per limit of the 95% CI would change our decision. We will al-
so calculate absolute numbers of true positives, true negatives,
false positives and false negatives, with ranges for these values
based on the CIs of the pooled estimates of sensitivity and speci-
ficity for various prevalences of plague, and we will make judge-
ments on imprecision using these calculations.
We will construct a 'Summary of findings' table, which will show the
main review findings along with the certainty of the evidence.
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A P P E N D I C E S
Appendix 1. MEDLINE (PubMed) search strategy
#1Search "Plague"[Mesh]
#2Search "Yersinia pestis"[Mesh]
#3Search plague Field: Title/Abstract
#4Search ((#3) OR "Yersinia pestis"[Mesh]) OR "Plague"[Mesh]
#5Search diagnosis [sh]
#6Search diagnosis or diagnostic* or detect* Field: Title/Abstract
#7Search "Diagnostic Techniques and Procedures"[Mesh]
#8Search RDT* Field: Title/Abstract
#9Search "Enzyme-Linked Immunosorbent Assay"[Mesh]
#10Search ELISA Field: Title/Abstract
#11Search lateral flow Field: Title/Abstract
#12Search "Chromatography, Affinity"[Mesh]
#13Search immunochromatograp* Field: Title/Abstract
#14 Search (((#13) OR #12) OR #11 OR #10 OR #9 OR #8 OR #7 or #6 OR #5
#15Search (#14) AND #4
This is the preliminary search strategy for MEDLINE (PubMed). It will be adapted for other electronic databases. We will report all search
strategies in full in the final version of the review.
Appendix 2. Data extraction form
 
Study ID First author
Year of publication
Journal of publication
Setting Country
Plague prevalence and endemicity in study setting
Study start and end dates
Study design Whether patients were enrolled prospectively or retrospectively
Sampling strategy (consecutive or random)
Inclusion and exclusion criteria
Target condition Any form of plague or a particular form of plague (bubonic, septicaemic, pneumonic), with case de-
finitions
Participants Sample size
Characteristics: age, gender, comorbidities
Signs and symptoms presented
Recent prior antibiotic treatment
Index test Brand name, target antigen, batch numbers
Which biological sample was tested (urine, sputum, bubo aspirate)?
Transport and storage condition
Need for sample preparation
Who performed the test (including any special training provided)?
Where was the test performed (field or laboratory)?
Threshold considered for positive result?
Reference standard Which reference standard was used (culture, PCR, serology, combination)?
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Which biological sample was tested (blood, urine, sputum, bubo aspirate)?
Who performed the reference standard test(s) (including training level)?
Where was the test performed?
How many observers or repeats were used?
Time between RDT and reference test?
Blinding of operator to RDT result?
Has the laboratory received quality accreditation by an external agency?
Index and reference stan-
dard test results
Numbers of true positives, false positives, true negatives and false negatives
Number of uninterpretable or doubtful results
Notes Source of funding
Anything else of relevance
  (Continued)
 
Abbreviations: PCR: polymerase chain reaction; RDT: rapid diagnostic test.
Appendix 3. Tailored QUADAS-2 tool
 
Item Yes No Unclear
Domain 1: Patient selection
Was a consecutive
or random sam-
ple of patients en-
rolled?
If the study reported consecutive enrolment or
random sampling of patients presenting with
suspicion of plague.
If patients were purposefully
selected, for example based
on previous test results.
If insufficient information
to make a decision on how
patients were selected.
Was a case-control
design avoided?
This item will always be ‘Yes' because we will ex-
clude case-control studies from this review.
Not applicable. Not applicable.
Did the study
avoid inappropri-
ate exclusions?
If no patients were excluded after inclusion in
the study, or if exclusions are clearly described
and appropriate (for example exclusion of the
patients with a known diagnosis).
If specific populations who
would be representative of
field conditions were exclud-
ed.
If unreported or insuffi-
cient information to make
a decision.
Did the study con-
sidered prior ad-
ministration of an-
tibiotics?
If patients who received antibiotics prior to sam-
ple collection were excluded.
If patients who received an-
tibiotics prior to sample col-
lection were included.
If unreported or insuffi-
cient information to make
a decision.
Could the selection of patients have introduced bias?Risk of bias
(high, low, or un-
clear) ‘High’ if at least one of the above signalling
questions is ‘No’, indicating that there is a con-
cern.
‘Low’ if the answer to all
three signalling questions is
‘Yes’.
‘Unclear’ if the answer
to at least one signalling
question is ‘Unclear’ and
none are answered ‘No’.
Are there concerns that the included patients do not match the review question?Applicability con-
cerns
(high, low, or un-
clear)
‘High’ if the included participants are inherent-
ly different from the patients who would be ex-
pected to receive the RDT.
‘Low’ if the included partici-
pants are suspected to have
plague and match those who
would be expected to receive
the test.
‘Unclear’ if there is insuf-
ficient information on pa-
tient characteristics to
make a decision.
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Domain 2: Index test
Were the index
test results inter-
preted without
knowledge of the
results of the ref-
erence standard?
If RDT was performed fully blinded to the refer-
ence standard result.
If reference standard result
was known prior to interpre-
tation of RDT result.
If blinding to reference
standard result was not
explicitly stated.
If a threshold was
used, was it pre-
specified?
If a threshold is pre-specified. If a threshold is not pre-spec-
ified.
If unreported.
Could the conduct or interpretation of the index test have introduced bias?Risk of bias
(high, low, or un-
clear) ‘High’ if the answer to either of the above sig-
nalling questions is ‘No’, indicating that there is
a concern.
‘Low’ if the answer to both
signalling questions is ‘Yes’.
‘Unclear’ if the answer
to at least one signalling
question is ‘Unclear’ and
none are answered ‘No’.
Are there concerns that the index test, its conduct, or interpretation differs from the review question?Applicability con-
cerns
(high, low, or un-
clear)
‘High' if the index test is not performed in field
conditions, or if the study describes inappropri-
ate storage conditions for the index test as de-
scribed by the manufacturer.
‘Low' if the study describes
suitable storage conditions
for the index test as de-
scribed by the manufactur-
er and that the index test is
designed for testing biologi-
cal samples for plague and is
used in field conditions.
‘Unclear' if there is insuffi-
cient information to make
a decision.
Domain 3: Reference standard
Is the reference
standard likely to
correctly classify
the target condi-
tion?
This item will always be ‘Yes’ because a correct
reference standard is part of the inclusion crite-
ria of this review.
Not applicable. Not applicable.
Were the refer-
ence standard re-
sults interpreted
without knowl-
edge of the results
of the index tests?
This item will always be ‘Yes’ because all the ref-
erence standards (culture, PCR, and serology)
are objective tests with no room for subjective
interpretation of test results.
Not applicable Not applicable
Could the reference standard, its conduct, or its interpretation has introduced bias?Risk of bias
(high, low, or un-
clear) ‘High’ if the answer to either of the above sig-
nalling questions is ‘No’, indicating that there is
a concern.
‘Low’ if the answer to both
signalling questions is ‘Yes’.
‘Unclear’ if the answer
to at least one signalling
question is ‘Unclear’ and
none are answered ‘No’.
Are there concerns that the target condition as defined by the reference standard does not match the review
question?
Applicability con-
cerns
(high, low, or un-
clear) We will answer this question as ‘low’ for all studies because diagnosis of plague by culture, PCR or paired serol-
ogy does match the review question.
  (Continued)
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Domain 4: Flow and timing
Was there an ap-
propriate inter-
val between index
test and reference
standard?
If no antibiotic was administered between sam-
ple collection for index test and reference stan-
dard, and if transportation of samples was less
than 7 days. We felt that the introduction of an-
tibiotics was more relevant than time between
collection of samples for both tests, as patients
with suspicion of plague will be started on an-
tibiotics as early as possible, and might affect re-
sults (of culture mainly).
If antibiotherapy was started
between sample collection
for RDT and reference stan-
dard for a significant propor-
tion of patients, or if trans-
portation of samples was
more than 7 days on average.
If there is insufficient in-
formation to make a deci-
sion.
Did all patients re-
ceive a reference
standard?
If all the participants received a reference stan-
dard.
If participants did not receive
a reference standard.
If there is insufficient in-
formation to determine
whether or not all patients
received a reference stan-
dard.
Did all patients
receive the same
reference stan-
dard?
If all the participants received the same refer-
ence standard.
If participants did not receive
the same reference standard.
If there is insufficient in-
formation to determine
whether or not all patients
received the same refer-
ence standard.
Were all patients
included in the
analysis?
If there were no withdrawals or exclusions (num-
ber of participants in the two-by-two table
matches the number of participants recruited
into the study) or if sufficient explanation was
given for any discrepancy.
If withdrawals or exclusions
are not explained or account-
ed for.
In unreported or there is
insufficient information to
make a decision.
Could the patient flow have introduced bias?Risk of bias
(high, low, or un-
clear) ‘High’ if at least one of the above signalling
questions is ‘No’, indicating that there is a con-
cern.
‘Low’ if the answer to all
above signalling questions is
‘Yes’.
‘Unclear’ if the answer
to at least one signalling
question is ‘Unclear’ and
none are answered ‘No’.
Applicability con-
cerns
Not applicable.
  (Continued)
 
Abbreviations: PCR: polymerase chain reaction; RDT: rapid diagnostic test.
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